These changes may lead to a range of changes across dopamine and serotonin neurotransmitter systems across a wide range of brain networks (88, 124, 125, 129)
Kannan R, Kuhlenkamp JF, Jeandidier E, Trinh H, Ookhtens M, Kaplowitz N
Real-world data splits the pattern by body type: leaner, non-diabetic users stop the drug more often and restart it less often than users with type 2 diabetes, while diabetic users regain less weight but lose more blood-sugar control. Retatrutides curve is expected to be steeper given the glucagon-arm fourth force the others dont carry
Confocal microscopy (CAU Kiel) was supported by the DFG (INST257/640-1FUGG)
Chemosphere 249:126121
Patience and consistency are essential for this particular benefit